5.8714
Tenax Therapeutics Inc stock is traded at $5.8714, with a volume of 5,752.
It is up +1.23% in the last 24 hours and down -9.53% over the past month.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$5.80
Open:
$5.85
24h Volume:
5,752
Relative Volume:
0.16
Market Cap:
$21.32M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3491
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+14.23%
1M Performance:
-9.53%
6M Performance:
+20.56%
1Y Performance:
+68.72%
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TENX
Tenax Therapeutics Inc
|
5.8714 | 21.32M | 0 | -14.56M | -12.46M | -16.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-24-24 | Initiated | Leerink Partners | Outperform |
Oct-14-24 | Initiated | Guggenheim | Buy |
Sep-30-24 | Initiated | William Blair | Outperform |
May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Dec-16-14 | Initiated | MLV & Co | Buy |
Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Form SC 13G/AStatement of Beneficial Ownership by Certain Investors: [Amend] - ADVFN
SEC Form DEF 14A filed by Tenax Therapeutics Inc. - Quantisnow
Form DEF 14A TENAX THERAPEUTICS, INC. For: Apr 24 - StreetInsider
Tenax Therapeutics Advances Cardiopulmonary Therapies - TipRanks
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - The Globe and Mail
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com - Defense World
Oxygen Biotherapeutics, Inc. : Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast - marketscreener.com
Teanx Therapeutics plans secondary offering - MSN
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha
Tenax Therapeutics (TENX) Files Prospectus for Stock Resale - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com - Defense World
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan
What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World
Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World
Q1 Earnings Estimate for TENX Issued By William Blair - Defense World
Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Research Analysts Set Expectations for TENX Q1 Earnings - Defense World
When (TENX) Moves Investors should Listen - news.stocktradersdaily.com
Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bluefield Daily Telegraph
Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost - Stock Titan
Tenax Therapeutics Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com - Defense World
Tenax Therapeutics (TENX) to Release Earnings on Thursday - Defense World
Plastic Fencing Market to be Driven by Growing Residential and Commercial Construction Activities, Exclusive Research by The Insight Partners - GlobeNewswire Inc.
Tenax Therapeutics (NASDAQ:TENX) Given “Outperform” Rating at William Blair - Defense World
Promising Developments and Financial Backing Drive Buy Rating for Tenax Therapeutics - TipRanks
What is Roth Capital’s Estimate for TENX FY2024 Earnings? - Defense World
Roth Capital Predicts Weaker Earnings for Tenax Therapeutics - Defense World
(TENX) Proactive Strategies - news.stocktradersdaily.com
Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewswire
Tenax Therapeutics announces $25M private placement - MSN
Tenax Therapeutics prices 378,346 shares at $6.04 in private placement - TipRanks
Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103 - TipRanks
Tenax Therapeutics secures $25 million in private placement - Investing.com India
Tenax Therapeutics Announces $25 Million Private Placement -March 05, 2025 at 08:54 am EST - Marketscreener.com
Tenax Therapeutics secures $25 million in private placement By Investing.com - Investing.com UK
Tenax Therapeutics Secures $25 Million From RTW Investments For Phase 3 Clinical Trials - StockTitan
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - Yahoo Finance
Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffs - Endpoints News
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
Can Tenax Therapeutics' Conference Appearance Signal New Cardiovascular Treatment Progress? - StockTitan
Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017 - ACCESS Newswire
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):